Ovarian Cancer

Biotechnology company selects contract manufacturer for therapeutic antibody

Published in Cancer Weekly, September 7th, 2004

Morphotek Inc. has entered into an agreement for Baxter Healthcare Corporation to support the development and manufacture of its lead targeted cancer therapeutic antibody, MORAb-003, which is being developed by Morphotek for the treatment of ovarian and other cancers.

MORAb-003 is a monoclonal antibody that specifically recognizes a cell surface antigen over-expressed in 90% of all ovarian cancers and a subset of other epithelial cancers.

Through the use of its proprietary Morphodoma technology, Morphotek has successfully optimized this antibody.

The antibody was obtained from an ongoing collaboration with The Ludwig Institute For...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2004-09-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry